Efficacy of vitamin E in children with immunotolerant-phase chronic hepatitis B infection

Basit Öğe Kaydı
dc.contributor.authorDikici, Bünyamin
dc.contributor.authorDagli, Abdullah
dc.contributor.authorUcmak, Hasan
dc.contributor.authorBilici, Meki
dc.contributor.authorEce, Aydin
dc.date.accessioned2024-04-24T17:11:33Z
dc.date.available2024-04-24T17:11:33Z
dc.date.issued2007
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground: The purpose of the present paper was to investigate the efficacy of vitamin E in children with immunotolerant-phase chronic hepatitis B virus (CHB) infection. Methods: Fifty-eight immunotolerant children were prospectively and randomly recruited into two groups. Group 1 (study group) included 30 patients who received vitamin E at a dose of 100 mg/day throughout 3 months; group 2 (control group) contained 28 patients who did not receive any medication. Comparison of serological, virologic, and biochemical response ratios were done at the end of the therapy and after 6 months of vitamin E discontinuation. Results: Mean alanine transaminase (ALT) values in group 1 at the beginning of the therapy, 3 months after the therapy initiation and 6 months after discontinuation were 30.4 +/- 7.3 IU/L, 31.3 +/- 7.8 IU/L and 32.1 +/- 8.5 IU/L, respectively. The mean hepatitis B virus (HBV)-DNA load of group 1 at onset, and at the third and ninth months of the treatment were 3106 +/- 718 pg/mL, 3530 +/- 137 pg/mL and 3364 +/- 1246 pg/mL, respectively. These changes in both ALT and HBV-DNA values did not reach significant levels (P > 0.05). In group 2, mean ALT values at the beginning of therapy, and at the third and ninth months were 28.0 +/- 1.8 IU/L, 34.6 +/- 8.1 IU/L, and 34.1 +/- 7.0 IU/L, respectively (P > 0.05), and mean viral load of HBV-DNA was 4227 +/- 1435 pg/mL, 3368 +/- 2673 pg/mL, and 3018 +/- 2814 pg/mL, respectively (P > 0.05). There was no statistically significant difference between group 1 and group 2 at the third and ninth months in the mean ALT values and viral load of HBV-DNA (P > 0.05). Hepatitis B s antigen and hepatitis B e antigen clearance or hepatitis B s antibody and hepatitis B e antibody seroconversion were not observed in either group. Conclusion: As a first study investigating the effect of vitamin E in children with immunotolerant CHB infection, no beneficial effect could be demonstrated. Different immunomodulator protocols should be considered for future investigations.en_US
dc.identifier.doi10.1111/j.1442-200X.2007.02419.x
dc.identifier.endpage607en_US
dc.identifier.issn1328-8067
dc.identifier.issn1442-200X
dc.identifier.issue5en_US
dc.identifier.pmid17875084
dc.identifier.scopus2-s2.0-34548670512
dc.identifier.scopusqualityQ3
dc.identifier.startpage603en_US
dc.identifier.urihttps://doi.org/10.1111/j.1442-200X.2007.02419.x
dc.identifier.urihttps://hdl.handle.net/11468/17594
dc.identifier.volume49en_US
dc.identifier.wosWOS:000249493400011
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofPediatrics International
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectChildrenen_US
dc.subjectChronic Hepatitis Ben_US
dc.subjectImmunotolerant Phaseen_US
dc.subjectTherapyen_US
dc.subjectVitamin Een_US
dc.titleEfficacy of vitamin E in children with immunotolerant-phase chronic hepatitis B infectionen_US
dc.titleEfficacy of vitamin E in children with immunotolerant-phase chronic hepatitis B infection
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu